P&G Signs Wellness Deal With Dose

P&G Signs Wellness Deal With Dose - p&g dose — P&G Signs Wellness Deal With Dose

The wellness sector is currently undergoing a significant wave of consolidation, highlighted by Procter & Gamble’s recent agreement to acquire supplement brand Thorne for $3.8 billion. This transaction serves as a strong signal that while the category is expanding, the list of companies attractive enough for major acquisition is surprisingly short. Days after the Thorne announcement, reports indicated that Dose, the Miami-based wellness-shot brand, is exploring a sale that could value the company near $1 billion.

P&G agreed to buy Thorne from L Catterton’s Flagship Fund, with Perella Weinberg advising on the sale, which is expected to close later this year. L Catterton originally took Thorne private for $680 million in 2023 after the company had briefly traded publicly at a $525 million valuation. After less than two years, that stake is set to return more than $3 billion for the firm. Thorne’s revenue had topped $500 million by 2025, built over four decades on a channel many direct-to-consumer brands never touch: healthcare practitioners recommending the product directly to patients.

A Shift in Strategy

Dose is reportedly working with the same bank, Perella Weinberg, on its sale process. The brand is profitable, generating more than $200 million in revenue a year, and is backed by Unilever Ventures among other investors. This activity follows other recent moves in the space. Unilever acquired gummy vitamin brand Grüns for $1.2 billion earlier in 2026, and private equity firm Bansk Group bought wellness shot brand So Good So You for an undisclosed sum.

For founders observing these headlines, the takeaway is distinct. Being in a growing category gets a brand into the room, but it does not guarantee the check. The scarce resource in the current market is not consumer demand, which is abundant, but a business model that turns that interest into reliable, data-backed repeat behavior that a large corporation can actually underwrite.

The Filter for Buyable Brands

Mike Ross, PwC’s U.S. consumer markets deals leader, noted that CPG conglomerates are getting far more intentional about what belongs in their portfolios. He stated that growth is not enough, and that large buyers are filtering out brands that lack specific structural advantages. The mechanism behind Thorne’s valuation is instructive. Its growth came from four decades of practitioners trusting it enough to put their own reputations behind it, a relationship built without renting attention from a platform.

Thorne distinguishes itself through credentialed trust rather than paid media. The company’s own materials point to trust from thousands of professional athletes, more than 100 pro sports teams, and multiple U.S. national teams. When clinicians and athletes put their names behind a product, it creates a level of credibility that a competitor cannot replicate just by outspending it on advertising.

Owned Audiences and Data

A second factor is an audience the brand owns rather than rents. A practitioner’s referral or a national-team partnership is a relationship Thorne built directly, not one it pays a platform to access every month. This structure is the same gap hidden in platform-level growth numbers versus a much less flattering brand-level reality on social sites. Any wellness brand can build a smaller version of this through an expert advisory board or a real community that engages without a discount code.

The third element is proof over growth. Growth curves are common in a category this hot. However, first-party proof that customers keep coming back on their own is not. Thorne got acquired because of how it had already been built, mostly outside the standard direct-to-consumer playbook. It showed a buyer something specific that a competitor cannot fake overnight: a durable routine in a customer’s daily life.